Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

(2015) David R. Nelson et al.   HEPATOLOGY

O059 : Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir

(2015) H. Dvory-Sobol et al.   JOURNAL OF HEPATOLOGY

O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens

(2015) P. Krishnan et al.   JOURNAL OF HEPATOLOGY

The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance

(2014) Udayan Chatterji et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cyclophilin inhibition as potential therapy for liver diseases

(2014) Nikolai V. Naoumov   JOURNAL OF HEPATOLOGY

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

(2014) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

(2014) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

(2014) Mark S. Sulkowski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients

(2013) Jeremie Guedj et al.   HEPATOLOGY

Is genotype 3 of the hepatitis C virus the new villain?

(2013) Nicolas Goossens et al.   HEPATOLOGY

821 INTERFERON (IFN)-FREE ALISPORIVIR (ALV) HAS A BETTER OVERALL SAFETY PROFILE COMPARED TO IFN-CONTAINING TREATMENT: A POOLED ANALYSIS OF THE ALV DEVELOPMENT PROGRAM

(2013) L. Griffel et al.   JOURNAL OF HEPATOLOGY

Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trial

(2013) D. Shoeb et al.   JOURNAL OF HEPATOLOGY

Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3

(2013) E. B. Tapper et al.   JOURNAL OF VIRAL HEPATITIS

Completion of the entire hepatitis C virus life cycle in genetically humanized mice

(2013) Marcus Dorner et al.   NATURE

The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

(2013) Ralf Bartenschlager et al.   NATURE REVIEWS MICROBIOLOGY

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

(2013) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

(2013) Eric Lawitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Profile of alisporivir and its potential in the treatment of hepatitis C

(2013) Philippe Gallay et al.   Drug Design Development and Therapy

Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to Alisporivir

(2012) Jose A. Garcia-Rivera et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

(2012) Patrick Marcellin et al.   HEPATOLOGY

Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

(2012) Khayriyyah Mohd Hanafiah et al.   HEPATOLOGY

Role of Hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis

(2011) A. Probst et al.   JOURNAL OF VIRAL HEPATITIS

The global health burden of hepatitis C virus infection

(2011) Francesco Negro et al.   LIVER INTERNATIONAL

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

(2011) Markus Cornberg et al.   LIVER INTERNATIONAL

Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025

(2010) Isabelle Landrieu et al.   BIOCHEMISTRY

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

(2010) Lotte Coelmont et al.   PLoS One

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

(2009) Robert Flisiak et al.   HEPATOLOGY

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C

(2009) Pierre-Yves Bochud et al.   JOURNAL OF HEPATOLOGY

Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors

(2008) L. Coelmont et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY